NCT07178600View on ClinicalTrials.gov

Clinical Determinants and Adverse Reactions to Tropicamide/Phenylephrine in Hospitalized Patients.

RecruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

September 2, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Adverse Drug EffectPhenylephrineHypertensionCardiovascular ComplicationOphthalmologyOcular Discomfort
Interventions
DRUG

Ophthalmic administration of tropicamide/phenylephrine 8 mg/50 mg/mL.

Measurement of vital signs after ophthalmic administration of tropicamide/phenylephrine 8 mg/50 mg/mL

Trial Locations (1)

06800

RECRUITING

Instituto de Oftalmología FAP Conde de Valenciana, IAP Sede Centro, Mexico City

All Listed Sponsors
lead

Instituto de Oftalmología Fundación Conde de Valenciana

OTHER